Reduction in serum alkaline phosphatase levels by treatment with active vitamin D (alphacalcidol) in primary and secondary hyperparathyroidism and in euparathyroid individuals.

Plain-language guide to PMID 1947853 (1991): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc, hyperparathyroidism.

Key Facts

PMID: 1947853
Journal: Scandinavian journal of urology and nephrology
Year: 1991
Study type: Randomized Controlled Trial
Authors: Lind L et al. (4 authors)
DOI: 10.3109/00365599109107953

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism, published as a randomized controlled trial.

Raised levels of alkaline phosphatases (ALP) are seen in conditions with a high bone turn-over, such as in primary and secondary hyperparathyroidism (HPT).

Who Took Part

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

To study the effects of active vitamin D treatment on ALP, alphacalcidol (1-alpha-hydroxyvitamin D3), was given to patients with primary HPT as well as HPT secondary to chronic renal failure and also to healthy, euparathyroid subjects.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

Raised levels of alkaline phosphatases (ALP) are seen in conditions with a high bone turn-over, such as in primary and secondary hyperparathyroidism (HPT).

The subject headings attached to it are Calcium, Hydroxycholecalciferols, Hypercalcemia, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Failure, Chronic and Renal Dialysis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with hyperparathyroidism.

The publication is from 1991 (Scandinavian journal of urology and nephrology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.